Navigation Links
First CyberKnife System Sold in Switzerland
Date:4/11/2008

Renowned Clinic Invests in Extracranial Radiosurgery

SUNNYVALE, Calif., April 11 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced that the Hirslanden Clinic in Zurich, part of the renowned Hirslanden group of private hospitals, has purchased a CyberKnife System. This marks the first System sold in Switzerland, allowing patients greater access to the benefits of extracranial radiosurgery.

Since its beginning in the 1930s, the Hirslanden private hospital group has been a pioneer in the development of innovative treatment concepts. Hirslanden clinics continually adjust their medical and technical equipment according to current developments, as part of their contribution to improving the health and quality of life of their patients. The Hirslanden Clinic's purchase of a CyberKnife System is part of Hirslanden Hospital Group's further development of a stereotactic radiosurgery practice. The System will be utilized for both intracranial and extracranial treatments, particularly the non-invasive treatment of prostate cancer. Ideally the addition of the CyberKnife System will support the establishment of the Neurocenter Zurich, which will offer a full range of therapeutic options in neurological diseases.

"With the purchase of the CyberKnife, we can now offer the complete spectrum of a modern radiation-oncology program," said Dr. Christian von Briel, co-chairman of Hirslanden radiation-oncology "We are also very excited to start a scientific cooperation with the CyberKnife centre in Nice, France. We are confident that working with this academic hospital will be valuable for the development of our extracranial activity."

According to the
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Custom Learning Designs, Inc.(CLD) unveils the ... Tin Can API combined with its own proprietary ... leading developer of training content and solutions for ... , Tin Can API is a cost-effective learning ... more accurately measure the Return on Education (ROE) ...
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)...  MacroGenics, Inc. today announced that an abstract ... Fc-modified chimeric monoclonal antibody (MAb), in patients with ... be presented at the 2013 Annual Meeting of ... Developmental Therapeutics - Immunotherapy Oral Abstract Session on ... The presentation will describe the results of a ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... Campbell Alliance, the,leading management consulting firm specializing in ... Managed Markets Practice will,take a leadership role at ... Modeling Strategies hosted by the Center for Business,Intelligence ... 10 through 11 at,the Doubletree Hotel in Philadelphia, ...
... Biology 2008 Meeting, SAN DIEGO, April 3, ... Biothera, reduced the incidence of fever,and eliminated the ... school due to,the cold-like symptoms, researchers reported today ... Cox, Ph.D., Vice President of Research & Development ...
... by over ... 100%, year-over-year, ... ), manufacturer and marketer of state-of-the-art cardiac,surgery products and services, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The Company currently expects ...
Cached Biology Technology:Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 2Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies 3Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 2Wellmune WGP(R) Supplementation Alleviates Duration, Severity and 'Down Time' Due to Cold Symptoms 3ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 2ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million 3
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
(Date:5/20/2013)... DIEGO (May 20, 2013) - A novel ... headline the groundbreaking research that will be unveiled at ... Conference (NBC). The meeting takes place Monday, May 20 ... Hotel and Marina. , "The main goal of ... fight against a pathogen that causes the disease", explained ...
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... Market, Stantum,s SMK Series Will Let Vendors, ... SAN DIEGO, Sept. 23 Stantum Technologies,( ... today introduced a demo, evaluation and development board ... lets,users simultaneously move an unlimited number of fingers, ...
... 2008 A new study finds that environmental restoration ... study, published in Restoration Ecology, maintains that ... practice, more research should be done on whole ecosystems ... taking advantage of large restoration sites by conducting large-scale ...
... aromatase inhibitors to treat breast cancer or prevent its ... dietary supplement, researchers report. Genistein, a soy isoflavone ... can negate the effectiveness of aromatase inhibitors, which are ... promote tumor growth in some types of breast cancer. ...
Cached Biology News:Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2Lack of large-scale experiments slows progress of environmental restoration 2The dietary supplement genistein can undermine breast cancer treatment 2The dietary supplement genistein can undermine breast cancer treatment 3